ENB Therapeutics’ lead novel anti-cancer therapy, ENB-003, was found to be safe and showed promising anti-tumor activity, when given in combination with Keytruda (pembrolizumab), to adults with different types of advanced solid malignancies, including ovarian cancer and melanoma. These are the early findings of an open-label Phase 1/2 trial (NCT04205227) that has recently finished dosing the third group of patients participating in its dose-escalation phase. “We are very excited to observe the continued safety of…
You must be logged in to read/download the full post.
The post ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors appeared first on BioNewsFeeds.